We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Suvretta Capital Management
New York
$49.2M -$10.6M -384,000 -17%
HA
27
Homestead Advisers
Virginia
$49M -$904K -32,600 -2%
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$48.5M -$8.25M -297,566 -14%
Mitsubishi UFJ Trust & Banking
29
Mitsubishi UFJ Trust & Banking
Japan
$48.3M -$724K -26,131 -1%
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$46.6M -$2.36M -85,243 -5%
Invesco
31
Invesco
Georgia
$45.8M +$29.5M +1,062,833 +158%
Qube Research & Technologies (QRT)
32
Qube Research & Technologies (QRT)
United Kingdom
$44.3M +$25.2M +908,455 +118%
BGIM
33
Brandywine Global Investment Management
Pennsylvania
$43.2M +$45.4M +1,637,195 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$40.4M +$2.39M +86,248 +6%
GA
35
General Atlantic
New York
$39.6M – – –
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$39.4M +$29.5M +1,063,108 +246%
PCM
37
Patient Capital Management
Maryland
$37.6M +$127K +4,572 +0.3%
Franklin Resources
38
Franklin Resources
California
$36.7M +$4.57M +165,012 +13%
AllianceBernstein
39
AllianceBernstein
Tennessee
$34.6M -$3.7M -133,640 -9%
UBS Group
40
UBS Group
Switzerland
$33.9M +$16.2M +585,185 +84%
Aberdeen Group
41
Aberdeen Group
United Kingdom
$31.3M -$3.06M -110,391 -9%
ACM
42
ADAR1 Capital Management
Texas
$31.2M +$12.8M +460,031 +64%
RP
43
Regal Partners
Australia
$31.1M +$6.04M +217,774 +23%
Swiss National Bank
44
Swiss National Bank
Switzerland
$29.6M -$371K -13,400 -1%
Man Group
45
Man Group
United Kingdom
$26.6M +$22.5M +813,343 +413%
Sumitomo Mitsui Trust Group
46
Sumitomo Mitsui Trust Group
Japan
$26.2M +$1.72M +62,218 +7%
Deutsche Bank
47
Deutsche Bank
Germany
$25.8M +$11.4M +410,590 +72%
Marshall Wace
48
Marshall Wace
United Kingdom
$24.9M -$14.1M -510,060 -35%
Arrowstreet Capital
49
Arrowstreet Capital
Massachusetts
$24.8M +$1.59M +57,288 +6%
N
50
Nuveen
North Carolina
$24.6M -$1.25M -45,265 -5%
1
2
3 4 5

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.